Sector News

Catalent snaps up Bettera Brands for US$1B to expand gummy and softgel offerings

September 5, 2021
Life sciences

Catalent is addressing the rising demand for alternative delivery formats with the US$1 billion acquisition of Bettera Brands, which offers nutritional gummies, softgels and lozenges. The definitive agreement is with Highlander Partners, under which it will acquire Bettera Holdings, the parent company of Bettera Brands.

The transaction is expected to close by the end of 2021 and is subject to customary closing conditions.

The acquisition is a key strategic move for Catalent’s Consumer Health business, according to Dr. Aris Gennadios, president, softgel and oral technologies, Catalent.

“As an innovator in softgel and oral technologies, Catalent has a long-standing presence in the rapidly expanding consumer health and nutraceutical marketplace. This way, we can offer customers more product development opportunities and add manufacturing capacity in this dynamic and growing segment.”

“This acquisition allows us to significantly accelerate the growth of our consumer health business and offer customers access to the substantial potential in gummies, soft chews and lozenges, which are all experiencing double-digit growth,” adds Gennadios.

Expanding manufacturing capabilities
Bettera Brands, which is headquartered in Texas, maintains four US manufacturing operations in California, Virginia, New Jersey and Indiana.

Highlander formed Bettera Brands through a series of four acquisitions beginning in 2017 and shaped it into a manufacturer of high-quality ingredient nutritional vitamins, minerals and supplements.

“In 2017, we started with a simple investment thesis of creating manufacturing capabilities around fortified/functional products in consumer-preferred formats,” says Jeff Hull, president and CEO of Highlander Partners.

As consumers have become increasingly health-conscious, functional products in gummy, soft chew and lozenge delivery forms have developed and grown to become a significant part of the market,” he argues.

“Given the substantial advances in delivery technologies, along with the increased health awareness, consumers are embracing these experiential formats as part of their everyday wellness routine.”

Jeff Partridge, a partner with Highlander who also served as Bettera’s CEO, adds that the company has identified a need early on and quickly assembled assets and a management team to capitalize on the demand and growth.

“Developing certified facilities, maintaining strict compliance standards and creating highly technical R&D capabilities was not an easy task.”

Expansion moves
Catalent recently signed a commitment letter with the Science-Based Target initiative, joining the list of companies setting actionable, science-based greenhouse gas emission reduction targets to limit global warming.

The company previously released Optigel DR, a design for delayed-release softgel capsules that eliminates the need for a second coating step in the manufacturing process. This is done by combining pectin with gelatin.

This launch inspired Hofseth BioCare to develop a delayed-release formulation of its OmeGo fish oil along with Catalent.

Moreover, Catalent launched CosmoPod Duo, a softgel capsule for the delivery of topical skin treatments. Based on the company’s CosmoPod unit-dose twist-off capsule technology, the capsule features segregated compartments to accommodate two formulations into a single twist-off solution.

Edited by Kristiana Lalou

Source: nutritioninsight.com

comments closed

Related News

September 12, 2021

Sanofi to buy Kadmon for $1.9B, extending deal streak

Life sciences

The deal, announced Wednesday, has Sanofi paying $9.50 per share in cash for Kadmon, a roughly 77% premium to the biotech’s Tuesday closing price and 113% more than its average trading price over the last two months.

September 12, 2021

GSK, Pfizer and Johnson & Johnson race toward $10B-plus RSV vaccine market: analyst

Life sciences

RSV, or respiratory syncytial virus, has long been a top target for vaccine developers. While companies have suffered high-profile trial failures over the years, vaccines are now advancing through late-stage testing and could launch in 2023, SVB Leerink analyst Geoffrey Porges wrote to clients this week.

September 12, 2021

Google, Mayo Clinic build new type of AI algorithm to map interactions between areas of the brain

Life sciences

By monitoring which areas of the brain responded to localized electrical stimulation, scientists from the Google Research Brain Team and Mayo Clinic developed an artificial intelligence algorithm to map out the structure of brain networks.

Send this to a friend